Phone: 203-624-5606
Fax: 203-624-5627
Website: http://www.rib-x.com

rchaiger@rib-x.com
General Information
Rib-X Pharmaceuticals is a molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The company's drug discovery strategy exploits its proprietary high-resolution crystal structure on the 50S subunit of the ribosome, which performs an essential role in the fundamental process of protein synthesis. The 50S is the target for many clinically valuable classes of antibiotics, including those used to treat both community-acquired and hospital pathogens. The company's integrated research approach combines state-of-the-art, proprietary computational analysis, x-ray crystallography, medicinal chemistry, microbiology and biochemistry, allowing for the rapid synthesis of new classes of antibiotics, which avoid typical antibiotic resistance mechanisms. Rib-X's iterative approach has rapidly yielded several distinctive chemical classes which it intends to bring into clinical testing. As their products enter Phase II studies, Rib-S will seek commercialization partnerships. The company is currently well-positioned to develop a pipeline of differentiable products that are expected to address distinct markets for the treatment of bacterial infections.

Other Information
Ownership: Private
CT Employees: 45

Back